SWOG clinical trial number
SWOG-8592

Evaluation of Low -Dose Ara-C versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndrome,

Closed
Phase
Published
Abbreviated Title
Evaluation of Low -Dose Ara-C versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndrome,
Activated
07/01/1984
Closed
07/01/1988

Publication Information Expand/Collapse

1992

Evaluation of low dose cytarabine in the treatment of the myelodysplastic syndromes: A phase III intergroup study.

KB Miller;K Kyungmann;F Morrison;JN Winter;JM Bennett;RS Neiman;DR Head;PA Cassileth;MJ O'Connell Annals of Hematology 65:162-168

Phase III evaluation of low-dose cytosine arabinoside versus supportive care in the treatment of adults with myelodysplastic syndrome: An Intergroup study of the Eastern Cooperative Oncology Group and the Southwest Oncology Group - preliminary results.

JM Bennett;KB Miller;K Kim;S Morrison;JN Winter;P Cassileth;RS Neiman;D Head Myelodysplastic Syndrome Schmalzzl and Mufti, Springer-Verlag :253-258

1989

Pathogenetic implications of internuclear bridging in myelodysplastic syndrome. An Eastern Cooperative Oncology Group/Southwest Oncology Group Cooperative Study

DR Head;K Kopecky;JM Bennett;K Grenier;FS Morrison;KB Miller;MR Grever Cancer 64:2199-2202